文献速递中毒与环境急症重症综合管理与镇静镇痛

基于苯巴比妥的方案治疗内科ICU酒精戒断综合征:前后对照实施研究

Phenobarbital-Based Protocol for Alcohol Withdrawal Syndrome in a Medical ICU: Pre-Post Implementation Study.
PubMed 文献 · Crit Care Explor · 2023-04-18
一句话结论在内科ICU酒精戒断综合征患者中,基于苯巴比妥的方案较苯二氮䓬类方案缩短ICU住院时间35%、缩短住院时间50%,且需要插管和身体约束更少。

该单中心前后对照实施研究在内科ICU纳入102例以酒精戒断综合征为主要诊断的患者,比较静脉苯巴比妥方案(260 mg负荷,随后按需每15-30分钟给予130 mg,至理想体重15 mg/kg)与递增剂量苯二氮䓬类方案(目标CIWA-Ar评分<10)。苯巴比妥组中位ICU住院时间1.5天 vs 苯二氮䓬组2.3天(降低35%,p=0.009),住院时间3天 vs 6天(降低50%,p<0.001);校正合并症和临床因素后ICU住院时间减少40%(95%CI 25.8-53.5%)。苯巴比妥组辅助用药更少、插管更少(2% vs 19.6%,p=0.023)、身体约束更少(37.3% vs 56.9%,p=0.047)。作者认为短期内快速递增苯巴比妥剂量是治疗内科ICU酒精戒断综合征有效且安全的苯二氮䓬替代方案。

要点

  • 苯巴比妥组中位ICU住院时间1.5天(IQR 1.2-2.4) vs 苯二氮䓬组2.3天(IQR 1.4-4.8),降低35%(p=0.009)。
  • 苯巴比妥组中位住院时间3天(IQR 2.7-4) vs 苯二氮䓬组6天(IQR 4-10),降低50%(p<0.001)。
  • 校正合并症和临床因素后,苯巴比妥方案使ICU住院时间减少40%(95%CI 25.8-53.5%)。
  • 苯巴比妥组需要插管1/51(2%) vs 苯二氮䓬组10/51(19.6%)(p=0.023)。
  • 苯巴比妥组需要身体约束19/51(37.3%) vs 苯二氮䓬组29/51(56.9%)(p=0.047),辅助用药0.7(IQR 0.5-1) vs 2.5(IQR 2-3)(p<0.001)。

适用人群与场景

  • 纳入所有因酒精戒断综合征主要诊断收入内科ICU的患者;内科ICU为40张床的大学医学中心三级医院。
  • 每组半数患者因震颤谵妄入院。

诊断标准与关键阈值

  • 以临床酒精戒断评估量表修订版(CIWA-Ar)评分<10为目标。

处置流程与药物剂量

  • 苯巴比妥方案:静脉给予苯巴比妥260 mg,随后按需每15-30分钟给予130 mg,至理想体重15 mg/kg。
  • 苯二氮䓬类方案:递增剂量苯二氮䓬类,以达到CIWA-Ar评分<10。

研究设计与关键结果

  • 单中心前后对照方案实施研究,共纳入102例患者,苯巴比妥组51例、苯二氮䓬组51例,两组基线临床特征无差异。
  • 主要结局:苯巴比妥组中位ICU住院时间1.5天(IQR 1.2-2.4) vs 苯二氮䓬组2.3天(IQR 1.4-4.8),降低35%(p=0.009);中位住院时间3天(IQR 2.7-4) vs 6天(IQR 4-10),降低50%(p<0.001)。
  • 校正合并症和临床因素后,苯巴比妥方案使ICU住院时间减少40%(95%CI 25.8-53.5%)。
  • 苯巴比妥组辅助用药更少:0.7(IQR 0.5-1) vs 2.5(IQR 2-3)(p<0.001)。
  • 苯巴比妥组需要插管1/51(2%) vs 苯二氮䓬组10/51(19.6%)(p=0.023)。
  • 苯巴比妥组需要身体约束19/51(37.3%) vs 苯二氮䓬组29/51(56.9%)(p=0.047)。

证据类型、等级与局限

  • 证据类型:单中心前后对照方案实施研究。
  • 作者结论:短期内快速递增苯巴比妥剂量是治疗内科ICU酒精戒断综合征有效且安全的苯二氮䓬替代方案。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于因酒精戒断综合征收入内科ICU的患者,采用静脉苯巴比妥260 mg负荷、随后按需每15-30分钟给予130 mg至理想体重15 mg/kg的方案,与递增剂量苯二氮䓬类相比,可缩短ICU和住院时间、减少辅助用药、插管和身体约束。
  • 作者认为,短期内快速递增苯巴比妥剂量是治疗内科ICU酒精戒断综合征有效且安全的苯二氮䓬替代方案。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: We assessed the efficacy and safety of PB compared with benzodiazepine (BZD)-based protocols in treating AWS in MICU.

DESIGN: Single-center, pre-post protocol implementation study.

SETTING: The setting is a forty-bed MICU in a tertiary-level academic medical center.

PATIENTS: We included all patients admitted to the MICU with a primary diagnosis of AWS.

INTERVENTIONS: Intravenous PB 260 mg followed by 130-mg doses every 15-30 minutes as needed up to 15 mg/kg of ideal body weight versus escalating doses of BZD, to achieve a Clinical Institute Withdrawal Assessment Alcohol Scale-Revised score less than 10.

MEASUREMENTS AND MAIN RESULTS: ICU and hospital length of stay (LOS), in addition to safety measures were the main outcomes of the study. A total of 102 patients were included, 51 in the PB arm and 51 in the BZD arm. There were no differences in baseline clinical characteristics. Half the patients in each group were admitted with delirium tremens. The use of PB-based protocol was associated with 35% reduction in median ICU LOS (1.5 d [interquartile range, 1.2-2.4 d] vs 2.3 d [1.4-4.8 d]; p = 0.009) and 50% reduction in hospital LOS (3 d [2.7-4 d] vs 6 d [4-10 d]; p < 0.001). After adjustment for comorbidities and clinical factors, PB protocol decreased ICU LOS days by 40% (95% CI; 25.8-53.5%). PB group required fewer adjunctive medications to control symptoms (0.7 [0.5-1] vs 2.5 [2-3]; p < 0.001), less need for intubation (1/51 [2%] vs 10/10 [19.6%]; p = 0.023) and less need for physical restraint (19/51 [37.3%] vs 29/51 [56.9%]; p = 0.047), compared with the BZD group.

CONCLUSIONS: A protocol utilizing rapidly escalating doses of PB over a short period is an effective and safe alternative to BZD in treating AWS in MICU.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Alwakeel M, Alayan D, Saleem T, et al. Phenobarbital-Based Protocol for Alcohol Withdrawal Syndrome in a Medical ICU: Pre-Post Implementation Study. Crit Care Explor. 2023. PMID: 37091477. doi:10.1097/CCE.0000000000000898

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。